Belatacept - Bristol-Myers Squibb
Alternative Names: BMS-224818; LEA 29Y; NulojixLatest Information Update: 05 Nov 2023
At a glance
- Originator Bristol-Myers Squibb
- Developer Bristol-Myers Squibb; Emory University; National Heart, Lung and Blood Institute
- Class Antirheumatics; Immunoglobulin fusion proteins; Recombinant fusion proteins
- Mechanism of Action CD80 antigen inhibitors; T cell activation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Renal transplant rejection
- Phase II Lung transplant rejection
- Discontinued Liver transplant rejection; Rheumatoid arthritis
Most Recent Events
- 03 Mar 2023 No development reported - Phase-III for Renal transplant rejection (In adolescents, In children, Treatment-experienced) in France (IV)
- 22 Feb 2023 No development reported - Phase-III for Renal transplant rejection (In the elderly, Prevention, Treatment-experienced, In adults) in Switzerland, Sweden, Netherlands, Greece, Germany, France, Austria (IV) (Bristol-Myers Squibb pipeline, February 2023)
- 31 Aug 2022 Bristol-Myers Squibb in collaboration with Washington University School of Medicine and National Heart, Lung, and Blood Institute completes a phase II trial in Lung transplant rejection (Combination therapy, Prevention) in USA (IV) (NCT03388008)